Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 913

1.

Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.

Musumeci G, Rossini R, Lettieri C, Capodanno D, Romano M, Rosiello R, Guagliumi G, Valsecchi O, Gavazzi A, Angiolillo DJ.

Catheter Cardiovasc Interv. 2012 Sep 1;80(3):395-405. doi: 10.1002/ccd.23337. Epub 2012 Jan 10.

PMID:
22109961
2.

Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.

Cassese S, De Luca G, Villari B, Berti S, Bellone P, Alfieri A, Montinaro A, Quaranta G, Marraccini P, Piscione F; MATRIX Study Investigators.

Catheter Cardiovasc Interv. 2012 Sep 1;80(3):408-16. doi: 10.1002/ccd.23223. Epub 2011 Nov 9.

PMID:
21735531
3.

Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.

Tada T, Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Byrne RA, Kastrati A, Kadota K, Iwabuchi M, Shizuta S, Tazaki J, Shiomi H, Abe M, Ehara N, Mizoguchi T, Mitsuoka H, Inada T, Araki M, Kaburagi S, Taniguchi R, Eizawa H, Nakano A, Suwa S, Takizawa A, Nohara R, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kimura T; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators.

Circ Cardiovasc Interv. 2012 Jun;5(3):381-91. doi: 10.1161/CIRCINTERVENTIONS.111.967463. Epub 2012 May 22.

4.

Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).

Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G; PRODIGY Investigators.

JACC Cardiovasc Interv. 2014 Jan;7(1):20-8. doi: 10.1016/j.jcin.2013.09.008. Epub 2013 Dec 11.

5.

Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.

Yu X, Chen F, He J, Gao Y, Wu C, Luo Y, Zhang X, Zhang Y, Ren X, Lv S.

Coron Artery Dis. 2013 May;24(3):217-23. doi: 10.1097/MCA.0b013e32835c8f74.

PMID:
23425771
6.

Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.

Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A, De Micco F, Latronico MV, Pagnotta P, Condorelli G.

JACC Cardiovasc Interv. 2013 Nov;6(11):1166-75. doi: 10.1016/j.jcin.2013.06.010.

7.

Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.

Cutlip DE, Kereiakes DJ, Mauri L, Stoler R, Dauerman HL; EDUCATE Investigators.

JACC Cardiovasc Interv. 2015 Mar;8(3):404-10. doi: 10.1016/j.jcin.2014.10.017. Epub 2015 Feb 18.

8.

Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.

Jones DA, Rathod KS, Gallagher S, Weerackody R, Knight CJ, Rothman MT, Mathur A, Jain AK, Timmis AD, Wragg A.

Catheter Cardiovasc Interv. 2013 May;81(6):E237-44. doi: 10.1002/ccd.24513. Epub 2012 Nov 14.

PMID:
22707383
9.

Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).

Park KW, Kang SH, Park JJ, Yang HM, Kang HJ, Koo BK, Park BE, Cha KS, Rhew JY, Jeon HK, Shin ES, Oh JH, Jeong MH, Kim S, Hwang KK, Yoon JH, Lee SY, Park TH, Moon KW, Kwon HM, Chae IH, Kim HS.

JACC Cardiovasc Interv. 2013 Sep;6(9):932-42. doi: 10.1016/j.jcin.2013.04.022.

10.

A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.

Han YL, Zhang L, Yang LX, Liu HL, Qu P, Li WM, Jiang TM, Li SM, Jing QM, Zhang QY, Xu B, Li Y, Gao RL.

EuroIntervention. 2012 Nov 22;8(7):815-22. doi: 10.4244/EIJV8I7A124.

11.

Dual antiplatelet therapy in patients with a long coronary artery lesion over 30 mm: Determinants and impact on prognosis.

Manchuelle A, Delhaye C, Schurtz G, Sudre A, Hurt C, Bonello L, Puymirat E, Bauters C, Lemesle G.

Arch Cardiovasc Dis. 2015 Apr;108(4):235-43. doi: 10.1016/j.acvd.2014.11.004. Epub 2015 Feb 11.

12.

Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.

Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB 3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusmão M, Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL; OPTIMIZE Trial Investigators.

JAMA. 2013 Dec 18;310(23):2510-22. doi: 10.1001/jama.2013.282183.

PMID:
24177257
13.

Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.

Helft G, Le Feuvre C, Georges JL, Carrie D, Leclercq F, Eltchaninoff H, Furber A, Prunier F, Sebagh L, Cattan S, Cayla G, Vicaut E, Metzger JP.

Trials. 2013 Feb 21;14:56. doi: 10.1186/1745-6215-14-56.

14.

Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease.

Lee HJ, Yu CW, Hwang HK, Choi RK, Park JS, Li H, Ro YM.

Coron Artery Dis. 2013 Nov;24(7):542-8. doi: 10.1097/MCA.0b013e328363abbd.

PMID:
23994880
15.

Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.

Li Y, Han Y, Zhang L, Jing Q, Wang X, Yan G, Ma Y, Wang G, Wang S, Chen X, Yang L, Zhu G, Liu H, Jiang T.

Catheter Cardiovasc Interv. 2013 Jun 1;81(7):1127-33. doi: 10.1002/ccd.24649. Epub 2013 Feb 26.

PMID:
22945767
16.

Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.

Zhang Q, Wang XL, Liao ML, Hu J, Yang ZK, Ding FH, Zhang JS, Du R, Zhu TQ, Shen WF, Zhang RY.

Catheter Cardiovasc Interv. 2015 Mar;85 Suppl 1:762-9. doi: 10.1002/ccd.25864.

PMID:
25630513
17.

Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation.

Rossini R, Capodanno D, Lettieri C, Musumeci G, Nijaradze T, Romano M, Lortkipanidze N, Cicorella N, Biondi Zoccai G, Sirbu V, Izzo A, Guagliumi G, Valsecchi O, Gavazzi A, Angiolillo DJ.

Am J Cardiol. 2011 Jan 15;107(2):186-94. doi: 10.1016/j.amjcard.2010.08.067.

PMID:
21211596
18.

Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement.

Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, Schömig A, von Beckerath N, Kastrati A.

J Thromb Haemost. 2010 Feb;8(2):250-6. doi: 10.1111/j.1538-7836.2009.03709.x. Epub 2009 Nov 28.

19.
20.

Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).

Rangé G, Yayehd K, Belle L, Thuaire C, Richard P, Cazaux P, Barbou F, Köning R, Chassaing S, Teiger E, Berthier R, Decomis MP, Claudel JP, Delarche N, Brunel P, De Poli F, Dupouy P, Beygui F, Albert F, Collet JP, Montalescot G; VERIFRENCHY investigators.

Arch Cardiovasc Dis. 2014 Apr;107(4):225-35. doi: 10.1016/j.acvd.2014.03.004. Epub 2014 Apr 29.

Items per page

Supplemental Content

Write to the Help Desk